|
|
|
|
Developing powder injectables requires matching sterilization to product traits. Early cross-functional planning and tight contamination controls build sterility assurance before clinical work starts.
|
|
|
|
|
Fragmented drug development causes delays and added costs. Unifying API synthesis, fill-finish, and testing streamlines logistics, preserves product data, and accelerates regulatory timelines.
|
|
|
|
|
Scaling sterile fill-finish operations requires balancing tight clinical timelines with flexibility. Single-use formulation systems eliminate major capital costs, reduce cleaning burdens, and speed turnarounds without sacrificing product quality.
|
|
|
|
|
A fully integrated single‑site model unifies development, manufacturing, formulation, fill‑finish, and quality oversight to reduce handoff risk and speed progression from API to sterile drug product.
|
|
|
|
|
|
|
Automated isolators bring precision to clinical powder fill/finish operations. By reducing batch variability and contamination risks, they deliver accurate dosing and speed up clinical trials.
|
|
|
|
|
|
|
An integrated single‑site model unites API development, formulation, fill/finish, and quality systems to provide consistent, compliant support from discovery through commercialization.
|
|
|
|
|
|
|
